Paper Details

  1. Home
  2. Paper Details

Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.

Author: GenclerOnur Serdar, OztekinMehmet Fevzi, OztekinNese

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared the efficacy of pramipexole and ropinirole, potent nonergoline dopamine agonists, in treating Parkinson's disease. These medications are used for both monotherapy and as add-on therapy to levodopa. The study also evaluated the effects of these agents on depression and their safety profiles.
Paper Details　
Original Abstract of the Article :
Parkinson's disease is a progressive neurodegenerative disease characterized by motor and non-motor symptoms. Levodopa is the most effective drug in the symptomatic treatment of the disease. Dopamine receptor agonists provide sustained dopamin-ergic stimulation and have been found to delay the initi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.18071/isz.75.0039

データ提供：米国国立医学図書館（NLM）

Pramipexole vs. Ropinirole: Comparing Dopamine Agonists in Parkinson's Disease

The field of [Parkinson's disease] research is constantly searching for effective treatments to manage the debilitating symptoms of this neurodegenerative disease. This study compares the efficacy of two potent nonergoline dopamine agonists, pramipexole and ropinirole, in treating Parkinson's disease. The researchers investigated the effectiveness of these medications both as monotherapy and in combination with levodopa.

Comparing the Efficacy of Dopamine Agonists

The study aimed to compare the efficacy of pramipexole and ropinirole in managing motor symptoms and assessing their effects on depression. The researchers found that both pramipexole and ropinirole were effective in improving motor function in patients with Parkinson's disease, both as monotherapy and in combination with levodopa. However, the study did not find significant differences between the two dopamine agonists in terms of efficacy or safety.

Navigating the Treatment Landscape of Parkinson's Disease

This research provides valuable insights into the use of dopamine agonists in the management of Parkinson's disease. The study's findings suggest that both pramipexole and ropinirole are effective treatment options, offering similar benefits in terms of motor symptom improvement and safety. This research helps clinicians make informed decisions regarding the choice of dopamine agonist for individual patients with Parkinson's disease.

Dr.Camel's Conclusion

Just as a camel navigates a vast and challenging desert, researchers are diligently searching for effective treatments for Parkinson's disease. This study provides a helpful comparison of two dopamine agonists, pramipexole and ropinirole, highlighting their similar efficacy and safety profiles. This research helps clinicians navigate the complex treatment landscape of Parkinson's disease, providing valuable information for making informed decisions about the best course of treatment for individual patients.

Date :
  1. Date Completed 2022-02-04
  2. Date Revised 2022-03-23
Further Info :

Pubmed ID

35112520

DOI: Digital Object Identifier

10.18071/isz.75.0039

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.